OTCMKTS:SNPHY - Santen Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$13.82
▼ -0.01 (-0.07%)

This chart shows the closing price for SNPHY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Santen Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNPHY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNPHY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Santen Pharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.82.

This chart shows the closing price for SNPHY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Santen Pharmaceutical. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/21/2021Daiwa Capital MarketsUpgradeUnderperform ➝ Neutral
6/7/2021MizuhoUpgradeNeutral ➝ Buy
6/29/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral
12/9/2019Jefferies Financial GroupInitiated CoverageHold
(Data available from 7/25/2016 forward)

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Read More

Today's Range

Now: $13.82
Low: $13.66
High: $13.90

50 Day Range

MA: $13.62
Low: $12.84
High: $14.26

52 Week Range

Now: $13.82
Low: $12.50
High: $20.93

Volume

19,885 shs

Average Volume

56,031 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Santen Pharmaceutical?

The following equities research analysts have issued reports on Santen Pharmaceutical in the last twelve months: Daiwa Capital Markets, and Mizuho.
View the latest analyst ratings for SNPHY.

What is the current price target for Santen Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Santen Pharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Santen Pharmaceutical in the next year.
View the latest price targets for SNPHY.

What is the current consensus analyst rating for Santen Pharmaceutical?

Santen Pharmaceutical currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNPHY will outperform the market and that investors should add to their positions of Santen Pharmaceutical.
View the latest ratings for SNPHY.

What other companies compete with Santen Pharmaceutical?

Other companies that are similar to Santen Pharmaceutical include Chugai Pharmaceutical, JCR Pharmaceuticals, Kyowa Kirin, Orion Oyj and PT Kalbe Farma Tbk..

How do I contact Santen Pharmaceutical's investor relations team?

The company's listed phone number is 81 6 6321 7000. The official website for Santen Pharmaceutical is www.santen.com.